Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PENN, THWI, ARMH, PWRM, BMRN - Stock Report From DrStockPick.com!

drstock-2-3

signup3m

Penn National Gaming Inc. (Nasdaq:PENN) announced that it will release its 2010 fourth quarter financial results at 7:00 a.m. ET on Thursday, February 3, 2011 and will host a conference call and simultaneous webcast at 10:00 a.m. ET on Thursday, February 3, 2011. Both the call and webcast are open to the general public. The conference call number is 212/231-2926; please call five minutes in advance to ensure that you are connected prior to the presentation. Interested parties may also access the live call on the Internet at www.pngaming.com; allow 15 minutes to register and download and install any necessary software.

Penn National Gaming, Inc. and its subsidiaries own and manage gaming and pari-mutuel properties in the United States.

**************************************************

Go to fullsize image

Thwapr, Inc. (OTC.BB:THWI) a service for mobilizing and monetizing branded video content, today announced the roll out of an important new way for marketers to measure the success of their mobile video campaigns. Thwapr's new Analytics Dashboard provides extensive tracking and measurement of mobile video and SMS analytics with graphical charts and graphs that illustrate campaign successes and opportunities.

To view the Dashboard, marketers log in to a secure, custom branded Web portal to view mobile video statistics and analytic data which is updated dynamically and accessible at anytime. Key analytics and features in the Dashboard include:

Topline Statistics -- A summary of total mobile video subscribers, video views and uploads, and SMS messages distributed for full campaign period; date range search option for ad-hoc queries by day(s), week(s), month(s), etc.

Content statistics -- Graphical bar chart view of the most popular videos (30+ displayed); statistics for individual videos shown by title and identifier with respect to video views, video Twitter posts, and mobile videophone sharing (30+ displayed); date range search option for ad-hoc queries by day(s), week(s), month(s), etc.

Mobile Device and Carrier Statistics -- Graphical bar chart view of the most popular mobile devices (20+ displayed); statistics for the most popular mobile devices accessed by users (20+ displayed); graphical pie chart view of the most popular Tier 1 & Tier 2 carriers (US/Canada); date range search option for ad-hoc queries by day(s), week(s), month(s), etc.

Subscriber Statistics -- Graphical bar chart view of opt-in and opt-out mobile video SMS statistics; statistics for subscription (total and daily opt-in and opt-out, absolute and %); date range search option for ad-hoc queries by day(s), week(s), month(s), etc.

Founded in 2007, Thwapr is a mobile video sharing service that allows brands to mobilize and monetize content, extending its distribution reach while delivering the highest possible quality and user experience regardless of device, network or carrier. Founded by digital video pioneers from Apple, Avid and MTV, Thwapr's patent-pending "Share to Phone" technology is revolutionizing mobile video, while also revitalizing traditional media by incorporating branded mobile video into print, broadcast, billboards and radio. A cloud-based solution that does not require a download or app, Thwapr is making mobile video sharing easy, fast and fun for the hundreds of millions of consumers with Web-enabled mobile devices.

**************************************************

power3

Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer's and Parkinson's, to name a few.

Alzheimer's is one, among the common sort of dementia, an over-all term regarding loss of memory and various other intellectual abilities serious enough to interfere with routine daily life. Alzheimer's condition is the reason for 50 to 70 percent of dementia cases.

Alzheimer's disease just isn't an everyday aspect of increasing age, although the most significant identified risk factor is increasing age, and the most of individuals with Alzheimer's are 65 and older. Alzheimer's is just not a illness connected with senior years. As much as five percentage of people with the actual condition have early-onset Alzheimer's (also called younger-onset), which frequently appears when someone is in their 40s or 50s.

Soon after cancer of the skin, cancers of the breast is a very common cancer recognized in females. However breast cancer rates have decreased in recent times, even if physicians are not certain why. Nevertheless, for many women, breast cancer could be the condition they fear most.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

**************************************************

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease."We have a strong track record of quickly developing enzyme replacement therapies for unmet medical needs and expect to leverage our clinical and regulatory experience and manufacturing know-how in the development of BMN 701," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "There is a significant amount of interest in the medical community for a more effective treatment option for late-onset Pompe disease, and we believe, based on in vitro and in vivo nonclinical studies, that using our proprietary Glycosylation Independent Lysosomal Targeting, or GILT technology, BMN 701 has the potential to deliver more enzyme to lysosomes compared to traditional mannose-6-phosphate targeted approaches."

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates.

**************************************************

ARM (Nasdaq:ARMH) and IBM announced an agreement between the two companies to extend their collaboration on advanced semiconductor technologies to enable the rapid development of next generation mobile products optimized for performance and power efficiency. The resulting technology will provide a suite of optimized physical and processor IP by ARM tuned to IBM’s advanced manufacturing process down to 14nm; providing streamlined development and earlier introduction of advanced consumer electronics into the marketplace.

ARM Holdings plc designs microprocessors, physical intellectual property (NYSE:IP), and related technology and software, as well as sells development tools to enhance the performance of high-volume embedded applications.

***************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars in cash from a third party (Mohamad Nehmeh) for one (1) week of advertisement services for Thwapr, Inc. (OTC:THWI)

Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).

drstbc